Personalized regenerative medicine cell product “Autologous Multi –
Lineage Potential Cells (AMPC)” characteristics –
- US Patent Number 11,471,485
- Therapeutic Goods Administration (TGA) of Australian government health management agency agree physician to infuse AMPC for medical services
- Medical insurance by Lloyd's of London, UK
- AMPC manufacture by closed system
- No antibiotics, exogenous growth factors or genetic manipulations
- More than 2,000 cases of autologous infusion have been completed, none any serious adverse reactions
- AMPC is safety and significant medical effects